Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Links shared publicly online about this topic.

1,715
total visits

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

View full resource at news-medical.net

Tags: Diabetes Type 2 Medication, Stroke, Thrombotic Event, Drug, Clinical Trial, Januvia, Merck & Co.